SCHEMBL25488451

SCHEMBL25488451

CN(Cc1ccc(F)c(F)c1)C(C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 3/20 0.50
HTT P42858 3/20 0.42
ALDH1A1 P00352 2/20 0.37
LTA4H P09960 1/20 0.36
MAOA P21397 2/20 0.34
MAOB P27338 2/20 0.34
SLC6A4 P31645 2/20 0.34
HTR2A P28223 1/20 0.34
KDM4E B2RXH2 1/20 0.33
MITF O75030 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
CACNA1G O43497 1/20 0.33
CACNA1H O95180 1/20 0.33
CACNA1C Q13936 1/20 0.33
CACNA1I Q9P0X4 1/20 0.33
SLC6A2 P23975 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22651829 0.84 PYCR1 (0.39) RIPK1HTTALDH1A1LTA4HSLC6A4
SCHEMBL22651830 0.84 CNR2 (0.40) RIPK1HTTALDH1A1SLC6A4HTR2A
SCHEMBL25587767 0.84 CYP1A2 (0.40) RIPK1HTTALDH1A1LTA4HKDM4E
SCHEMBL25489343 0.80 HRH3 (0.37) RIPK1LTA4HCACNA1H
SCHEMBL23972532 0.79 HRH3 (0.50) RIPK1HTTALDH1A1SLC6A4HTR2A
SCHEMBL10294050 0.78 RIPK1 (0.50) RIPK1ALDH1A1LTA4H
SCHEMBL10294046 0.76 RIPK1 (0.55) RIPK1ALDH1A1SLC6A2SLC6A3
SCHEMBL23374698 0.74 RIPK1 (0.47) RIPK1HTTALDH1A1MAOAMAOB
SCHEMBL10294049 0.74 PYCR1 (0.48) HTTALDH1A1LTA4HSLC6A4HTR2A
SCHEMBL22763972 0.73 ALDH1A1 (0.47) HTTALDH1A1LTA4HKDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230146675-A1 PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS iTeos Belgium SA (BE) 2023-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230146675-A1 PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS ENTPD5, ENTPD1, SLC29A1 RIPK1 3534/4885HTT 3542/4885ALDH1A1 226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.